A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Active:	Yes
Cancer Type:	Lung Cancer Unknown Primary	NCT ID:	NCT06692738
Trial Phases:	Phase III	Protocol IDs:	D702BC00001 (primary) 2024-514281-39-00 ( Registry Identifier ) (REGISTR
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06692738

Summary

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in
combination with platinum-based chemotherapy for the first-line (1L) treatment of
patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC)
whose tumors express programmed death-ligand 1 (PD-L1).

Objectives

This is a Phase III, two-arm, randomized, double-blind, global, multicenter study
assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in
combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for
patients with squamous locally advanced or metastatic non-small cell lung cancer (mNSCLC)
whose tumors express PD-L1 (tumor cells (TC) = 1%).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.